Roche's new multiple sclerosis drug earned priority review status from the Food and Drug Administration, potentially moving up the drug's launch date, according to Reuters.
The agency's fast track review process was created to decrease the time it takes to put promising new medicines on the market.
The FDA granted priority review status for Roche's drug Ocrevus to treat both the relapsing-remitting and primary-progressive forms of MS. If approved, the drug would be the first treatment specifically approved to treat the primary-progressive form of the disease.
The Switzerland-based drug company originally estimated FDA approval for Ocrevus in early 2017. Now, the company expects approval by December 28.
More articles on the drug market:
Natco Pharma earns FDA approval for ulcer drug
BMS' bladder cancer drug granted breakthrough therapy designation
Cannabis-based epilepsy drug shows positive results in late-stage trial